Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.

Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L, Fahy JV, Jarjour N, Kazani S, Kim S, Kraft M, Lazarus SC, Lemanske RF Jr, Markezich A, Martin RJ, Permaul P, Peters SP, Ramsdell J, Sorkness CA, Sutherland ER, Szefler SJ, Walter MJ, Wasserman SI, Israel E; National Heart, Lung and Blood Institute's Asthma Clinical Research Network..

Lancet. 2009 Nov 21;374(9703):1754-64. doi: 10.1016/S0140-6736(09)61492-6.

2.

Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies.

Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M.

Lancet. 2007 Dec 22;370(9605):2118-25. Review.

PMID:
18156033
3.

Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial.

Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF Jr, Liggett SB, Martin RJ, Mitra N, Peters SP, Silverman E, Sorkness CA, Szefler SJ, Wechsler ME, Weiss ST, Drazen JM; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network..

Lancet. 2004 Oct 23-29;364(9444):1505-12.

PMID:
15500895
4.

beta-Adrenergic receptor polymorphisms and response to salmeterol.

Wechsler ME, Lehman E, Lazarus SC, Lemanske RF Jr, Boushey HA, Deykin A, Fahy JV, Sorkness CA, Chinchilli VM, Craig TJ, DiMango E, Kraft M, Leone F, Martin RJ, Peters SP, Szefler SJ, Liu W, Israel E; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network..

Am J Respir Crit Care Med. 2006 Mar 1;173(5):519-26. Epub 2005 Dec 1.

5.

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.

Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM.

J Allergy Clin Immunol. 2011 Aug;128(2):315-22. doi: 10.1016/j.jaci.2011.06.004.

PMID:
21807250
6.

Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.

Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH, Dorinsky PM.

J Allergy Clin Immunol. 2006 Oct;118(4):809-16. Epub 2006 Aug 28.

PMID:
17030231
7.

Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate.

Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, Anderson WH, Emmett AH, Ortega HG.

Am J Respir Crit Care Med. 2010 Apr 1;181(7):676-87. doi: 10.1164/200809-1511OC. Epub 2009 Nov 12.

PMID:
19910613
8.

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial.

Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF Jr, Sorkness CA, Kraft M, Fish JE, Peters SP, Craig T, Drazen JM, Ford JG, Israel E, Martin RJ, Mauger EA, Nachman SA, Spahn JD, Szefler SJ; Asthma Clinical Research Network for the National Heart, Lung, and Blood Institute..

JAMA. 2001 May 23-30;285(20):2583-93.

PMID:
11368732
10.

Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics.

Nielsen LP, Pedersen B, Faurschou P, Madsen F, Wilcke JT, Dahl R.

Respir Med. 1999 Dec;93(12):863-8.

PMID:
10653047
11.

Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.

D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI.

JAMA. 1994 May 11;271(18):1412-6.

PMID:
7909853
12.
13.

Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.

Kalra S, Swystun VA, Bhagat R, Cockcroft DW.

Chest. 1996 Apr;109(4):953-6.

PMID:
8635376
14.

Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study.

Wilding P, Clark M, Thompson Coon J, Lewis S, Rushton L, Bennett J, Oborne J, Cooper S, Tattersfield AE.

BMJ. 1997 May 17;314(7092):1441-6.

15.

Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children.

Chauhan BF, Chartrand C, Ni Chroinin M, Milan SJ, Ducharme FM.

Cochrane Database Syst Rev. 2015 Nov 24;(11):CD007949. doi: 10.1002/14651858.CD007949.pub2. Review.

PMID:
26594816
17.

Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.

Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, Fabbri LM, Rabe KF.

Lancet Respir Med. 2013 Mar;1(1):23-31. doi: 10.1016/S2213-2600(13)70012-2. Epub 2013 Mar 4.

PMID:
24321801
18.

Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness.

Rosenthal RR, Busse WW, Kemp JP, Baker JW, Kalberg C, Emmett A, Rickard KA.

Chest. 1999 Sep;116(3):595-602.

PMID:
10492259
19.

Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.

Kerstjens HA, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, Engel M, Bour L, Verkleij CB, Moroni-Zentgraf P, Bateman ED.

Lancet Respir Med. 2015 May;3(5):367-76. doi: 10.1016/S2213-2600(15)00031-4. Epub 2015 Feb 12.

PMID:
25682232
20.

Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases.

Murray JJ, Church NL, Anderson WH, Bernstein DI, Wenzel SE, Emmett A, Rickard KA.

Allergy Asthma Proc. 1999 May-Jun;20(3):173-80.

PMID:
10389550

Supplemental Content

Support Center